Electronic Supplementary Material (ESI) for RSC Medicinal Chemistry.
This journal is © The Royal Society of Chemistry 2023

Supporting Information

Dual FLT3/haspin kinase inhibitor based on potent 3*H*-pyrazolo[4,3-*f*]quinoline scaffold with activities against acute myeloid leukemia

Allison L. Kempen[1], Nickolas R. Brauer[1], Herman O. Sintim[1,2,3]*

[1]*Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN 47907*

[2]*Purdue Institute for Drug Discovery, 720 Clinic Drive, West Lafayette, IN 47907*

[3]*Purdue Institute for Cancer Research, 201 S. University St., West Lafayette, IN 47907*

Contents of Supporting Information:

^{1}H-NMR and ^{13}C-NMR spectra for final compounds

Compound **1** ^{1}H NMR



^{13}C NMR



Compound **2** ^{1}H NMR



^{13}C NMR



Compound **3** ^{1}H NMR



^{13}C NMR



Compound **4** ^{1}H NMR



^{13}C NMR



Compound **5** ^{1}H NMR



^{13}C NMR



Compound **6** ^{1}H NMR



^{13}C NMR



Compound **7** ^{1}H NMR



^{13}C NMR



Compound **8** ^{1}H NMR



^{13}C NMR



Compound **9** ^{1}H NMR



^{13}C NMR



Compound **10** ^{1}H NMR



^{13}C NMR



Compound **11** ^{1}H NMR



^{13}C NMR



Compound **12** ^{1}H NMR



^{13}C NMR



Compound **13** ^{1}H NMR



^{13}C NMR



Compound **14** (HSK205) ^{1}H NMR



^{13}C NMR



Compound **15** ^{1}H NMR



^{13}C NMR